Category: Eye On Washington
Revisiting an IDEA
U.S. Reps. Nydia Velázquez (D-N.Y.) and Steve Stivers (R-Ohio), along with U.S. Sens. Mazie K. Hirono (D-Hawaii) and Thom Tillis (R-N.C.), have reintroduced the Inventor Diversity for Economic Advancement Act (IDEA Act) before Congress.
Read More
After Iancu
The tenure of outgoing Director Andrei Iancu was lauded across many sectors of the U.S. patent system, perhaps with the exception of the tech sector. As we consider candidates for the next USPTO head, perhaps we should look to the political moment in which we find ourselves to guide our search.
Read More
Patent Applications Grew in 2020
Patent application filing activity increased slightly in the United States during 2020, despite the upheaval caused by the COVID-19 pandemic.
Read More
Iancu Says Goodbye
One day before Joe Biden was to be inaugurated as the 46th U.S. President, U.S. Patent and Trademark Office Director Andrei Iancu confirmed he is leaving his position.
Read More
The Plantable Pencil Saga
IPWatchdog spoke with Michael Stausholm about his experience trying to protect a growing brand in a world where fakes are proliferating, and most countries’ legal regimes have yet to catch up with the problem.
Read More
PTAB Rulemaking: Past, Present, Future
USPTO Director Andrei Iancu should be supported and encouraged for doing the right thing with the latest change, requiring that testimonial evidence be viewed neutrally.
Read More
Going Remote
From a truly national and international recruiting base, talent acquisition will be easier than ever thanks to the move to remote work. And from a tax standpoint, the savings could be enormous.
Read More
Devastating Loss
IP world reeling over death of former USPTO director Q. Todd Dickinson. Many remember him as the former under secretary of commerce for intellectual property and director of the U.S. Patent and Trademark Office during Bill Clinton’s second term.
Read More
PTAB Is Supreme
If the PTAB is necessary to rid the world of bad patents, it should not matter whether they were acquired by small and mid-size entities or acquired by large entities.
Read More
Patent Rights at Risk?
The patent system can spur research and development in a health crisis, but public health advocates may see patents as barriers to better patient health outcomes.
Read More
Lessons from COVID-19
Because medical diagnostics are no longer patentable in the United States, investors are uninterested. This causes a series of unfortunate cascading effects. We must correct U.S. innovation policy to ensure we are ready for the next pandemic.
Read More
